Management of Hypercalcemia of Malignancy

Initial Assessment and Treatment

The American College of Physicians recommends initiating immediate IV normal saline hydration followed by zoledronic acid 4 mg infused over 15 minutes as the cornerstone of treatment for moderate to severe hypercalcemia of malignancy 1, 2
Measure corrected serum calcium using the formula: Corrected calcium (mg/dL) = Total calcium (mg/dL) + 0.8 × [4.0 - patient albumin (g/dL)], or preferably measure ionized calcium directly 2
Classify severity to determine urgency: Mild (10-11 mg/dL), Moderate (11-13.5 mg/dL), Severe (>14 mg/dL) 1
Obtain diagnostic workup including serum intact PTH, PTHrP, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, phosphorus, magnesium, creatinine, and albumin 1, 2
Malignancy-associated hypercalcemia is characterized by suppressed iPTH levels, elevated PTHrP, and low or normal calcitriol levels 1, 2

Administer IV normal saline immediately to correct hypovolemia and promote calciuresis, targeting urine output ≥100 mL/hour (3 mL/kg/hour in children <10 kg) 1, 2, 3
Hydration should ideally start at least 48 hours before tumor-specific therapy when possible 4, 2
Zoledronic acid 4 mg IV infused over 15 minutes is the preferred first-line bisphosphonate, superior to pamidronate in efficacy and duration 1, 2, 3
Zoledronic acid normalizes calcium in approximately 50% of patients by day 4 and provides longer response duration than pamidronate 1, 2

Calcitonin 100 IU subcutaneously or intramuscularly provides rapid onset within hours but has limited efficacy and tachyphylaxis develops quickly 3
Denosumab 120 mg subcutaneously is indicated for bisphosphonate-refractory hypercalcemia or patients with renal insufficiency 1, 2
Denosumab reduces serum calcium in 64% of patients with bisphosphonate-refractory hypercalcemia 1, 2
Denosumab is preferred over bisphosphonates in patients with renal disease as it does not require renal dose adjustment 1

Monitor serum creatinine, calcium, and urinary albumin before and during bisphosphonate therapy 3, 2
Discontinue bisphosphonates if unexplained albuminuria >500 mg/24 hours, serum creatinine increases >0.5 mg/dL, or absolute creatinine >1.4 mg/dL in patients with normal baseline 2
Avoid NSAIDs and IV contrast media in patients with renal impairment to prevent further deterioration of kidney function 3
Perform baseline dental examination and monitor for osteonecrosis of the jaw with chronic bisphosphonate use 1, 2

Median survival after discovery of malignant hypercalcemia in lung cancer patients is approximately 1 month 1, 2
Treatment of the underlying malignancy is essential for long-term control of hypercalcemia 2